Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-confirmation, immunogenicity and safety study of the Clostridium difficile vaccine candidate VLA84 in adults ≥50 years
2014-003934-22Phase 2Completed
- Sponsor
- Valneva
- Start
- Oct 2014
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Clostridium difficile vaccine in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Valneva. Primary endpoint: Seroconversion rate for IgG against toxin A and toxin B at Day 56. Started Oct 2014; status: completed.
02
Drugs
Clostridium difficile vaccine
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2014-003934-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003934-22.